摘要
程序性死亡分子配体1(PD-L1)抑制剂等免疫疗法是治疗非小细胞肺癌(NSCLC)的一项重大进展。但由于缺乏明确的生物标志物来选择最佳的受益人群,因此该抑制剂只在约20%晚期NSCLC患者中起作用。与单药治疗比较,NSCLC患者结合常规和/或靶向治疗显示更好的安全性和疗效。笔者总结几种已批准用于NSCLC治疗的抗PD-L1药物,且强调抗PD-L1治疗与化学疗法、血管内皮生长因子抑制剂、靶向治疗,以及放射治疗等其他非免疫治疗相结合的临床研究进展。
With the rapid development of tumor immunity, immune therapies such as programmed death ligand-1 (PD-L1) inhibitors play an important role in the treatment of NSCLC. Because of the lack of the definite biomarkers to select the optimal responders, only approximately 20% of patients with advanced NSCLC would respond to single checkpoint inhibitors-based immunotherapy. In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments. In this review article, we summarized several anti-PD-L1 agents licensed for NSCLC treatment, and highlight the clinical progress in the combinatory therapy of anti PD-L1 therapy with chemotherapy, vascular endothelial growth factor inhibitors, targeted therapies, and radiation.
作者
金美花
李杨
Mei-hua Jin;Yang Li(Department of Pharmacy, Institute of Field Surgery Research, Daping Hospital of Army Military University, Chongqing, 400042, China)
出处
《中国现代医学杂志》
CAS
2019年第18期40-47,共8页
China Journal of Modern Medicine
关键词
癌
非小细胞肺
酶抑制剂
免疫疗法
治疗效果
carcinoma, non-small cell lung
enzyme inhibitors
immunotherapy
therapeutic effects
